Abstract
The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Aza Compounds / pharmacology
-
Drug Resistance, Bacterial
-
Fluoroquinolones
-
Gram-Negative Bacteria / drug effects*
-
Gram-Negative Bacteria / isolation & purification
-
Gram-Positive Cocci / drug effects*
-
Gram-Positive Cocci / isolation & purification
-
Humans
-
Microbial Sensitivity Tests / methods
-
Microbial Sensitivity Tests / standards
-
Moxifloxacin
-
Quinolines / pharmacology
-
Quinolones / chemistry
-
Quinolones / pharmacology*
-
Taiwan
Substances
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Quinolones
-
nemonoxacin
-
Moxifloxacin